Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Eli Lilly

Novo Nordisk is the developer behind Ozempic and Wegovy, both of which are seeing unprecedented demand. Eli Lilly's Mounjaro is challenging the competition, generating over $3 billion in sales since its launch last May.

These 2 Unstoppable Stocks Could Make You Richer in 2024 and Beyond

Weight-loss drug excitement went overboard in 2023. Novo Nordisk's Wegovy – which is known as Ozempic when used to treat diabetes – and Eli Lilly's Zepbound are the first effective treatments for obesity.

Ozempic overshoot will plump up bargain-hunters

The overall stock market rise likely helped boost Novo Nordisk's shares. A top Indian online marketplace is also working to halt illegal sales of Novo's weight loss drug Wegovy.

Why Novo Nordisk Stock Is Moving Higher Today

GlaxoSmithKline

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.

5 Big Drug Stocks That May Continue to Outperform in 2024

Pfizer

Understanding what's hot and what's not is key to investing in biopharma. Drugs like Ozempic are going to continue being very popular next year.

These Are the 3 Hottest Biopharma Trends of 2024. Should You Invest?

NetEase

Pinduoduo Inc - ADR

Stellantis N.V. 

Toyota Motor

We have selected five high-flying non-U.S. companies that have strong potential for 2024. These are: NVO, NTES, TM, PDD, STLA.

5 Non-U.S. Stocks to Buy as Wall Street Fires on All Cylinders

The Novo Nordisk (NYSE:NVO) Foundation, which has the controlling holding of Novo Nordisk, has announced an investment of around $265 million to establish a new initiative focused on enhancing vaccines for respiratory diseases. This move comes as the foundation's financial resources have significantly increased due to the success of Novo Nordisk's weight-loss drug, Wegovy.

Novo Nordisk owner channels some of Wegovy windfall into respiratory diseases

One of India's leading online marketplaces is working with pharma giant Novo Nordisk to tackle illegal sales of popular weight loss drug Wegovy, Reuters reported Monday, as its soaring popularity and strictly limited supply fosters a growing market for potentially dangerous fakes.

Fake Wegovy: Pharma Giant Novo Nordisk Reportedly Steps Up Efforts Tackling Illegal Weight Loss Drugs Sold Online

The Novo Nordisk Foundation, which controls drug maker Novo Nordisk, said on Monday it would commit up to 1.8 billion Danish crowns ($265 million) to setting up an initiative aimed at improving vaccines for respiratory diseases.

Novo owner commits $265 mln of Wegovy windfall to respiratory diseases

Indian online marketplace IndiaMART has been removing unauthorized listings of Novo Nordisk's blockbuster weight-loss drug Wegovy after holding talks with the Danish drugmaker in early October, a source familiar with the matter told Reuters.

Exclusive: IndiaMART is working with Novo Nordisk to halt illegal Wegovy sales -source

Advanced Micro Devices

ASML Hld

LVMH Moet Hennessy Louis Vuitton

UnitedHealth Group

Visa

The magnificent seven stocks have had a fantastic 2023. Those firms dominate Silicon Valley and are amongst seven of the largest eight firms globally, as measured by market capitalization.

The New Magnificent 7: 7 Stocks Rising to Prominence

Arecor Therapeutics PLC (AIM:AREC)'s chief executive Sarah Howell said the company is at an advanced stage of recruiting patients for phase one trials of rapid ultra-concentrated insulin and should be ready to announce the results at the end of the first quarter of 2024.    The new and ultra-concentrated formulation developed by Arecor has been designed to accelerate the absorption of insulin, a hormone made by the pancreas, after injection.

Arecor's novel drug formulations could help cut burden on hospitals

In studies, Eli Lilly's Mounjaro has demonstrated that it is more effective in helping people lose weight than Ozempic. Street analysts project the weight-loss market to be massive.

Ozempic Isn't the Best Weight-Loss Treatment Anymore. Here's Why That Shouldn't Matter to Novo Nordisk Investors.

Arcturus Therapeutics

With such a high demand for items that can improve our longevity and health, biotechnology is at the forefront of today's innovation. Biotech products allow us to better understand the human body and how we can improve functioning within the body.

3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024

Merchants Bancorp

Perdoceo Education

Perdoceo Education (PRDO), Novo Nordisk (NVO) and Merchants Bancorp (MBIN) have been selected as the top picks with a high net income ratio.

3 Best Profitable Stocks to Invest in Using Net Income Ratio

Weight loss drugs are expected to be some of the best-selling pharma products of all time by 2030. Eli Lilly and Novo Nordisk are the frontrunners in this space.

Better Weight Loss Stock: Eli Lilly or Novo Nordisk?

Novo Nordisk reported strong Q3 results, beating analyst consensus on both top line and earnings. The SELECT CVOT study showed that Wegovy/Ozempic treatment may reduce the risk of death from cardiovascular disease by 18%. Novo Nordisk's investments in supply capacity expansion position the company for supercharged growth through 2030.

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Amgen

AstraZeneca

Bristol-Myers

Gilead Sciences

Merck

Novartis

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Novo Nordisk and Eli Lilly have pulled ahead in the race for a slice of the weight-loss drugs market, expected to be worth $100 billion by the end of the decade, and rivals are looking to catch up through acquisitions and trials.

Novo, Lilly rivals explore booming weight-loss drug market entry

Novo Nordisk was first to market with its blockbuster weight loss treatment Wegovy. Doctors have prescribed Eli Lilly's diabetes treatment for weight loss.

Could Eli Lilly Beat Novo Nordisk in the Billion-Dollar Weight Loss Market?

Axonics ModulationTechnologies Inc

Cava Group, Inc.

Goldman Sachs Small Cap Core Equity ETF

iRhythm Technologies

Meritage Homes

Sweetgreen

Shake Shack

Tenable Holdings Inc

Wingstop

Most exchange-traded funds are passively managed — they are designed to mirror the performance of stock indexes and typically have low management fees. They can work out very well for investors, which has been the case for funds that track the S&P 500.

Goldman Sachs money manager digs into three themes for long-term growth

JP Morgan has identified its top picks in the European pharmaceuticals and biotechnology sector for 2024, spotlighting large, mid, and small-cap companies poised for significant growth. Among its top tips were Novo Nordisk, AstraZeneca PLC (LSE:AZN), and Merck KGaA in the large-cap space, Argenx and DiaMonTech in mid-caps, and MorphoSys AG in small caps.

AstraZeneca and Novo Nordisk among the top picks of this top US bank - here's why

Having developed a blockbuster diabetes treatment that has gained huge traction in the weight loss market, Novo Nordisk (NYSE:NVO) is now expanding its focus to include the prevention of obesity, according to the Financial Times. CEO Lars Fruergaard Jørgensen is spearheading efforts to explore why certain individuals are more prone to weight gain, the paper said.

Novo Nordisk: From diabetes to weight loss to obesity preventions

Denmark's Saxo Bank makes a tradition of making “outrageous predictions,” which every once in a while comes true. The bank counts as a win its 2022 prediction that the plan to end fossil fuels will get a rain check, and its 2019 call that Germany will enter a recession.

No more exercising? President RFK Jr.? Here's one bank's outrageous predictions for 2024

The year 2023 was a breakout year for glucagon-like peptide (GLP-1) weight-loss drugs in the medical sector, led by the popularity of Ozempic. Celebrity usage and social media exposure have caused Novo Nordisk A/S NYSE: NVO Semaglutide drug Ozempic to go mainstream and viral as countless consumers try the medication that was originally approved for type 2 diabetes patients.

Ozempic vs. Mounjaro:: Battle of the bulge

News for Novo Nordisk Stock (NVO)